NASDAQ · Medical - Pharmaceuticals

Damora Therapeutics, Inc. (GLTO) Stock

$21.58 -3.36% NASDAQ: GLTO Healthcare

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.

Valuation

MetricValue
Price$21.58
Market Cap$34.47M
P/E Ratio-0.17
P/B Ratio1.45
P/S Ratio0.00
EPS (TTM)$-152.99
52-Week High$38.33
52-Week Low$2.01
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-122.40%
ROA-43.91%
ROCE-46.73%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio22.48

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-52.0M$-61.0M$-40.0M$-22.0M$-211.0M
Net Profit$-52.0M$-62.0M$-38.0M$-21.0M$-210.0M
EPS$-50.75$-61.04$-36.08$-18.53$-152.99
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$122.0M$73.0M$38.0M$17.0M$261.0M
Total Liabilities$5.0M$11.0M$6.0M$1.0M$20.0M
Cash$63.0M$33.0M$21.0M$14.0M$258.0M
Borrowings$1.0M$1.0M$0$0$0

Latest News

4 Chandigarh University Law Graduates Become Judicial Officers, 244 Secure Jobs at Corporate Law Firms PR Newswire · Jul 23, 2026 Registration Now Open: Free Global Webinar on Dual-HA Biostimulation Featuring Live Clinical Demonstration PR Newswire · Jul 23, 2026 Joinable Labs Launches Joinable Propagator™, the Trusted Knowledge Foundry for the Agentic Enterprise Business Wire · Jul 23, 2026 Macy's has a 'lightweight' $100 8-piece comforter set for just $30 that's 'perfect for summer' TheStreet · Jul 23, 2026 ANSR and HFS Research Release Findings from the Inaugural HFS GCC Generative Enterprise Market Pulse Study; India's GCCs Emerge as Transformation Partners, but Ownership and AI-Native Operating Models Will Define the Next Leap PR Newswire · Jul 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-52.0M$-43.0M$-37.0M$-19.0M$-7.0M
Investing Cash Flow$-48.0M$12.0M$22.0M$12.0M$-17.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-101.0M$-30.0M$-11.0M$-7.0M$243.0M
Free Cash Flow$-53.0M$-43.0M$-37.0M$-19.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA2.12
FCF Yield-72.19%
Quick Ratio22.48
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXP $1.40 -1.40% -0.36 $2.22M 0.00%
ADIL $3.33 +1.22% -1.14 $3.20M 0.00%
APRE $0.62 -1.16% -0.47 $4.06M 0.00%
APVO $4.21 -4.10% -0.06 $9.21M 0.00%
BCDABioCardia, Inc. $0.84 -1.11% -0.83 $4.88M 0.00%

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Damora Therapeutics, Inc. is headquartered in US.

Damora Therapeutics, Inc. (GLTO) stock trades at $21.58 with a market capitalization of $34.47M. The stock is valued at a price-to-earnings (P/E) ratio of -0.17, price-to-book of 1.45, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.01 and $38.33, and currently trades 43.7% below its 52-week high.

On profitability, Damora Therapeutics, Inc. generates a return on equity (ROE) of -122.40%, return on capital employed of -46.73%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: galecto.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides